Furosemide reverses multidrug resistance status in bladder cancer cells in vitro

Journal of Clinical Pathology

Volumn 59, Issue 9, 2006, Pages 912-915

  Speers, A G ^b   Lwaleed, B A ^a   Featherstone, J M ^a   Sallis, B J ^b   Cooper, A J ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; EPIRUBICIN; FUROSEMIDE; MITOMYCIN C;

ARTICLE; BLADDER CANCER; CANCER CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DILUTION; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG SENSITIVITY; DRUG UPTAKE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MOLECULAR CLONING; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CELL DEATH; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FUROSEMIDE; HUMANS; MICROSCOPY, CONFOCAL; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 33748882396     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.033100     Document Type: Article

References (22)

1. Burnand K, Young A. The new Aird's companion in surgical studies, 2nd edn. London: Churchill Livingstone, 1998:1081-9.
2. Richie JP. Intravesical chemotherapy. Treatment selection, techniques, and results. Urol Clin North Am 1992;19:521-7.
3. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996;155:1233-8.
4. Scheper RJ, Scheffer GL, Flens MJ. Transporter molecules in multidrug resistance. Cytotechnology 1996;19:187-90.
5. Nakagawa M, Emoto A, Nasu N, et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 1997;157:1260-5.
6. Varadi A, Szakacs G, Bakos E, et al. P glycoprotein and the mechanism of multidrug resistance. In: Mechanism of drug resistance in epilepsy: lessons from oncology. Novartis Foundation Symposium. Chichester: Wiley, 2002:54-68.
7. Weaver JL, Szabo G Jr, Pine PS, et al. The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter. Int J Cancer 1993;54:456-61.
8. Jennings AM, Solomon LZ, Sharpe P, et al. Estramustine reversal of resistance to intravesical epirubicin chemotherapy. Eur Urol 1999;35:327-35.
9. Roepe PD. pH and multidrug resistance. In: The tumour microenvironment: causes and consequences of hypoxia and acidity. Novartis Foundation Symposium. Chichester: Wiley, 2001:232-50.
10. Ibrahim S, Peggins J, Knapton A, et al. Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation. Anticancer Res 2001;21:847-56.
11. Lewin J, Cooper A, Birch B. Progesterone: a novel adjunct to intravesical chemotherapy. BJU Int 2002;90:736-41.
12. Duffy PM, Hayes MC, Cooper A, et al. Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines. Br J Cancer 1996;74:906-9.
13. Duffy PM, Hayes MC, Gatrell SK, et al. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study. Br J Urol 1996;77:824-9.
14. Hayes MC, Birch BR, Cooper AJ, et al. Cellular resistance to mitomycin C is associated with overexpression of MDR-1 in a urothelial cancer cell line (MGH-U1). BJU Int 2001;87:245-50.
15. McGovern F, Kachel T, Vijan S, et al. Establishment and characterization of a doxorubicin-resistant human bladder cancer cell line (MGH-U1R). J Urol 1988;140:410-4.
16. Duffy PM, Hayes MC, Cooper A, et al. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model. Br J Urol 1996;77:819-23.
17. Knuchel R, Hofstadter F, Jenkins WE, et al. Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy. Cancer Res 1989;49:1397-401.
18. Cooper AJ, Hayes MC, Duffy PM, et al. Multidrug resistance evaluation by confocal microscopy in primary urothelial cancer explant colonies. Cytotechnology 1996;19:181-6.
19. Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy Drugs 1993;45:788-856.
20. Laurence DR, Bennett PN. Kidney and urinary tract. Clinical pharmacology. 7th edn. London: Churchill Livingstone, 1992:459-69.
21. Davies CL, Duffy PM, MacRobert AJ, et al. Localization of anthracycline accumulation in sensitive and resistant urothelial tumor cell lines. Cancer Detect Prev 1996;20:625-33.
22. Featherstone JM, Speers AG, Lwaleed BA, et al. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines. BJU Int 2005;95:1091-8.